<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4374">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04578210</url>
  </required_header>
  <id_info>
    <org_study_id>RELEASE</org_study_id>
    <nct_id>NCT04578210</nct_id>
  </id_info>
  <brief_title>Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia</brief_title>
  <acronym>RELEASE</acronym>
  <official_title>A Phase I/II Dose-escalation Multi Center Study to Evaluate the Safety of Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in coronaviruS pnEumonia and/or Lymphopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidad Autonoma de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Miguel Hernandez de Elche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biocruces Bizkaia Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I/II clinical trial using adoptive cell therapy with NK cells or memory T&#xD;
      cells in patients affected by COVID-19.&#xD;
&#xD;
      Severe cases with COVID-19 present a dysregulated immune system with T cell lymphopenia,&#xD;
      specially NK cells and memory T cells, and a hyper-inflammatory state.&#xD;
&#xD;
      This clinical trial proposes the use of cell therapy for the treatment of patients with worse&#xD;
      prognosis due to SARS-CoV-2 infection (those with pneumonia and/or lymphopenia). This is an&#xD;
      innovative and a non-pharmacological intervention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this phase I/II trial natural killer (NK) cells or memory T lymphocytes will be infused&#xD;
      from donors who have recovered from COVID-19 and have complete resolution of symptoms for at&#xD;
      least 14 days.&#xD;
&#xD;
      There will be two arms based on the biology of the donor and the patient:&#xD;
&#xD;
        1. Infusion of NK cells which are cells of the innate immune system that can eliminate&#xD;
           virally infected cells.&#xD;
&#xD;
        2. Infusion of memory T cells which have the SARS-COV-2 memory T cell repertoire.&#xD;
&#xD;
      The investigators expect a quick recovery of the patients with pneumonia or lymphopenia for&#xD;
      two reasons:&#xD;
&#xD;
        1. NK cells act quickly after a viral infection. The number and function of NK cells&#xD;
           correlates with the severity of another coronavirus infection, Severe Acute Respiratory&#xD;
           Syndrome (SARS), originated in China in 2002.&#xD;
&#xD;
           Moreover, the investigators have previous successful experience with other viruses such&#xD;
           as CMV, EBV and HHV-6.&#xD;
&#xD;
        2. The pool of memory T cells will increase in patients. Memory T cell levels are low in&#xD;
           these patients. These lymphocytes have long-life memory, which upon reencountering&#xD;
           SARS-CoV-2 will induce enhanced effector function resulting in greater protection of the&#xD;
           patient.&#xD;
&#xD;
      Patients who have recovered from COVID-19 are the ideal donor candidates because they have&#xD;
      immune cells with memory against SARS-CoV-2. Therefore, the infusion of NK and memory T cells&#xD;
      from these donors will increase the pool of cells with cytotoxicity to virally infected&#xD;
      cells, and will increase the pool of memory cells that respond quicker to a previously&#xD;
      encountered stimulus.&#xD;
&#xD;
      This will impact in saving thousands of lives, releasing hospital beds, reducing the costs of&#xD;
      a national health system and improving the economy of a locked-down country.&#xD;
&#xD;
      Cell therapies are safe and cost-effective and successfully used in other diseases. the&#xD;
      investigators need new innovative treatments where others have failed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 4, 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This Phase I/II escalating-dose clinical trial is a randomized study to determine safety, tolerability, alloreactivity and efficacy of cell therapy with adoptive cell therapy of NK cells or memory T cells in patients affected by COVID-19 Donors will be patientsrecovered from COVID-19 Will be 2 arms&#xD;
A: allogeneic T memory cells&#xD;
B: allogeneic NK cells&#xD;
There will be two consecutive phases:&#xD;
The first dose escalation focuses on determining safety and the recommended dose for the second segment Phase I: Patients with SARS-CoV-2+ pneumonia and/or lymphopenia and O2Sat ≤ 94% on room air at screening, with no oxygen required or with an oxygen need of ≤ 2.5 lpm in nasal cannula, will be selected This phase has a single ascending dose design with up to 3 planned dose levels for each arm&#xD;
The second phase extends the safety study Phase II: Patients with SARS-CoV-2+ pneumonia and/or lymphopenia and O2Sat ≤ 94% on room air at screening, requiring or not oxygen supplementation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of DLTs in all patients during the study treatment, until 21 days after cell infusion and the MTD</measure>
    <time_frame>3 months</time_frame>
    <description>Any grade 3 or higher toxicity with an attribution of definitely or probably related to the infusion of the cells and any lower grade toxicity that increases to a grade 3 or higher as a direct result of the cell infusion.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Corona Virus Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: allogeneic T memory cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive memory T cells</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: allogeneic NK cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive NK cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>T memory cells and NK cells</intervention_name>
    <description>Single infusion of NK or memory T cells from a healthy donor recovered from COVID-19 (dose escalation).</description>
    <arm_group_label>Arm A: allogeneic T memory cells</arm_group_label>
    <arm_group_label>Arm B: allogeneic NK cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients ≤ 80 years of age.&#xD;
&#xD;
          -  Patient with diagnosis of COVID-19 infection with laboratory confirmation by&#xD;
             reverse-transcription PCR (RT-PCR) of SARS-CoV-2 &lt;72 hours prior to study entry.&#xD;
&#xD;
          -  Onset of symptoms &lt; 10 days prior to administration of study treatment.&#xD;
&#xD;
          -  No more than 72 hours (3 days) of hospitalization before study treatment&#xD;
             administration.&#xD;
&#xD;
          -  Phase I criteria: Patients requiring hospitalization for COVID-19, with pneumonia&#xD;
             diagnosed with chest radiograph or computed tomography imaging or lymphopenia&#xD;
             (absolute lymphocyte counts below 1.2 x 109cells /L) AND O2Sat ≤ 94% on room air at&#xD;
             screening, no oxygen requirement or with an oxygen need of ≤ 2.5 lpm in nasal cannula.&#xD;
&#xD;
          -  Phase II criteria: Patients requiring hospitalization with pneumonia diagnosed with&#xD;
             chest radiograph or computed tomography imaging or lymphopenia (absolute lymphocyte&#xD;
             counts below 1.2 x 109cells /L) AND O2Sat ≤ 94% on room air at screening, requiring or&#xD;
             not oxygen supplementation (nasal cannula, oxygen mask with reservoir, non-invasive&#xD;
             ventilation, etc), but excluding mechanical ventilation.&#xD;
&#xD;
          -  Have a negative pregnancy test documented prior to enrollment (for females of&#xD;
             childbearing potential).&#xD;
&#xD;
          -  Be willing and able to comply with study procedures.&#xD;
&#xD;
          -  Patients with the ability to comprehend and sign the informed consent&#xD;
&#xD;
          -  Written informed consent obtained prior to any screening procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrolled in another Clinical Trial for COVID19.&#xD;
&#xD;
          -  Rapidly progressive disease with anticipated life-expectancy &lt;72 hours.&#xD;
&#xD;
          -  Patients requiring mechanical ventilation.&#xD;
&#xD;
          -  Patients with multiorgan failure.&#xD;
&#xD;
          -  Mild-moderate (grade ≥ 3) organ impairment (liver, kidney, respiratory), according to&#xD;
             criteria from the National Cancer Institute (NCI CTCAE version 5.0).&#xD;
&#xD;
          -  Severe and/or uncontrolled concurrent medical disease that in the opinion of the&#xD;
             investigator could cause unacceptable safety risks or compromise compliance with the&#xD;
             protocol.&#xD;
&#xD;
          -  Have a known history of human immunodeficiency virus infection, Hepatitis B or&#xD;
             Hepatitis C; testing is not required in the absence of prior documentation or known&#xD;
             history.&#xD;
&#xD;
          -  Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a&#xD;
             female after conception and until the termination of gestation, confirmed by a&#xD;
             positive hCG laboratory test.&#xD;
&#xD;
          -  Any other condition that, in the opinion if the Investigator, may interfere with the&#xD;
             efficacy and/or safety evaluation of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Víctor Alelú Hernández, Mr</last_name>
      <phone>91 497 53 59</phone>
      <email>victor.alelu.ucicec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Pérez Martínez, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos Solano, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cristina Eguizabal, Dra</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bernat Soria, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 1, 2020</study_first_submitted>
  <study_first_submitted_qc>October 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 8, 2020</study_first_posted>
  <last_update_submitted>October 14, 2020</last_update_submitted>
  <last_update_submitted_qc>October 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Lymphopenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

